BRPI0810482A2 - Métodos de produção de proteína usando compostos antissenescência - Google Patents

Métodos de produção de proteína usando compostos antissenescência

Info

Publication number
BRPI0810482A2
BRPI0810482A2 BRPI0810482-4A2A BRPI0810482A BRPI0810482A2 BR PI0810482 A2 BRPI0810482 A2 BR PI0810482A2 BR PI0810482 A BRPI0810482 A BR PI0810482A BR PI0810482 A2 BRPI0810482 A2 BR PI0810482A2
Authority
BR
Brazil
Prior art keywords
sensence
compounds
production methods
protein production
protein
Prior art date
Application number
BRPI0810482-4A2A
Other languages
English (en)
Inventor
Jose Manuel Gomes
Yen-Tung Luan
Gregory Walter Hiller
Wenge Wang
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39493848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0810482(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0810482A2 publication Critical patent/BRPI0810482A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
BRPI0810482-4A2A 2007-04-23 2008-04-22 Métodos de produção de proteína usando compostos antissenescência BRPI0810482A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91338207P 2007-04-23 2007-04-23
PCT/US2008/061125 WO2008131375A1 (en) 2007-04-23 2008-04-22 Methods of protein production using anti-senescence compounds

Publications (1)

Publication Number Publication Date
BRPI0810482A2 true BRPI0810482A2 (pt) 2014-10-07

Family

ID=39493848

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0810482-4A2A BRPI0810482A2 (pt) 2007-04-23 2008-04-22 Métodos de produção de proteína usando compostos antissenescência
BRPI0810511-1A2A BRPI0810511A2 (pt) 2007-04-23 2008-04-22 Utilização de baixa temperatura e / ou baixo ph em cultura celular

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0810511-1A2A BRPI0810511A2 (pt) 2007-04-23 2008-04-22 Utilização de baixa temperatura e / ou baixo ph em cultura celular

Country Status (26)

Country Link
US (2) US9988662B2 (pt)
EP (2) EP2139986B1 (pt)
JP (3) JP5557736B2 (pt)
KR (3) KR20140132016A (pt)
CN (3) CN101679943A (pt)
AR (2) AR066238A1 (pt)
AU (2) AU2008242633B2 (pt)
BR (2) BRPI0810482A2 (pt)
CA (2) CA2685552C (pt)
CL (2) CL2008001156A1 (pt)
CO (2) CO6241165A2 (pt)
DK (2) DK2139987T5 (pt)
ES (2) ES2646090T3 (pt)
HK (2) HK1142095A1 (pt)
HU (1) HUE034776T2 (pt)
IL (2) IL201719A (pt)
MX (2) MX2009011363A (pt)
PA (2) PA8777701A1 (pt)
PE (2) PE20090731A1 (pt)
PL (2) PL2139987T3 (pt)
PT (2) PT2139986T (pt)
RU (2) RU2009138226A (pt)
SI (2) SI2139987T1 (pt)
TW (2) TW200902708A (pt)
WO (2) WO2008131375A1 (pt)
ZA (1) ZA200907426B (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI548747B (zh) 2006-09-13 2016-09-11 艾伯維有限公司 細胞培養改良
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
US20090042253A1 (en) * 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
ES2535734T3 (es) 2008-10-20 2015-05-14 Abbvie Inc. Aislamiento y purificación de anticuerpos mediante cromatografía de afinidad con la proteína A
TW201028433A (en) 2008-10-20 2010-08-01 Abbott Lab Viral inactivation during purification of antibodies
WO2011068993A1 (en) * 2009-12-02 2011-06-09 Acceleron Pharma Inc. Compositions and methods for increasing serum half-life of fc fusion proteins.
PT2563906T (pt) 2010-04-26 2018-02-16 Novartis Ag Processo para cultivo de células cho
BR112013018751B1 (pt) * 2010-12-28 2021-01-05 Chugai Seiyaku Kabushiki Kaisha (Chugai Pharmaceutical Co., Ltd.) método para modular o nível de componentes de homogeneidade de uma proteína, método para produzir uma proteína desejada, medicamento e método para preparação do mesmo
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
RU2718986C2 (ru) * 2013-03-15 2020-04-15 Дженентек, Инк. Композиции клеточных культур с антиоксидантами и способы получения полипептидов
US9765139B2 (en) * 2013-03-26 2017-09-19 Coherus Biosciences, Inc. Perfusion method for manufacturing etanercept
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
USD759075S1 (en) * 2014-04-11 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
USD759076S1 (en) * 2014-04-18 2016-06-14 Nutonian, Inc. Display screen with graphical user interface
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
US9908932B2 (en) 2014-10-15 2018-03-06 Alexion Pharmaceuticals, Inc. Methods of shifting an isoelectric profile of a protein product and uses thereof
AR104050A1 (es) * 2015-03-26 2017-06-21 Chugai Pharmaceutical Co Ltd Proceso de producción con iones de cobre controlados
TW202330904A (zh) 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
CN107460221B (zh) * 2016-06-02 2021-01-15 正大天晴药业集团股份有限公司 一种降低抗pd-l1抗体中蛋白聚合物的细胞培养方法
WO2018073365A1 (en) 2016-10-19 2018-04-26 F. Hoffmann-La Roche Ag Method for producing an immunoconjugate
EP3571289A1 (en) * 2017-02-17 2019-11-27 Lonza Ltd A method for producing biologic product variants
WO2019079165A1 (en) * 2017-10-16 2019-04-25 Regeneron Pharmaceuticals, Inc. RAMAN IN SITU SPECTROSCOPY SYSTEMS AND METHODS FOR CONTROLLING PROCESSING VARIABLES IN CELL CULTURES
CA3118398A1 (en) * 2018-11-02 2020-05-07 WuXi Biologics Ireland Limited Cell culture process by intensified perfusion with continuous harvest and without cell bleeding
JP2022522816A (ja) * 2019-03-04 2022-04-20 アムジエン・インコーポレーテツド 高分子量種のインビボでの可逆性
BR112022013255A2 (pt) 2020-01-09 2022-09-06 Mersana Therapeutics Inc Conjugados anticorpo-fármaco específicos de sítio com ligantes contendo peptídeo
WO2022254319A1 (en) * 2021-06-01 2022-12-08 Pfizer Inc. Cell culture method for producing sfgfr3 polypeptide
KR20230051921A (ko) * 2021-10-12 2023-04-19 프레스티지바이오로직스 주식회사 항체 집단의 제조 방법

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5610033A (en) 1990-04-25 1997-03-11 Novo Nordisk A/S Method of producing proteins with FVIII activity and/or FVIII derivatives
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
WO1992009298A1 (en) * 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
ES2176484T3 (es) * 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
EP2305027B1 (en) * 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
JP3090657B1 (ja) 1999-08-09 2000-09-25 伸子 蓮山 ゼオライト製造方法およびゼオライト製造装置
AUPR038200A0 (en) * 2000-09-26 2000-10-19 Beta Peptide Foundation Pty Ltd, The Compositions and methods for delaying, preventing, rejuvenating or reversing senescence
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
US20040058445A1 (en) * 2001-04-26 2004-03-25 Ledbetter Jeffrey Alan Activation of tumor-reactive lymphocytes via antibodies or genes recognizing CD3 or 4-1BB
US6544076B2 (en) 2001-07-10 2003-04-08 Alan L. Pocrass Dual function RJ connector
DE60236014D1 (de) * 2001-11-19 2010-05-27 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
CA2417689C (en) 2002-03-05 2006-05-09 F. Hoffmann-La Roche Ag Improved methods for growing mammalian cells in vitro
MXPA04009381A (es) * 2002-03-27 2005-01-25 Immunex Corp Metodos para incrementar la produccion de polipeptidos.
GB0208041D0 (en) 2002-04-08 2002-05-22 Lonza Biologics Plc Method of culturing animal cells
EP2287288B1 (en) 2002-07-09 2012-11-07 Baxter International Inc. Animal protein free media for cultivation of cells
JP4510938B2 (ja) 2002-07-15 2010-07-28 イミュネックス・コーポレーション 哺乳動物細胞により産生されるタンパク質のシアル酸付加を調節する方法および培地
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
PL377731A1 (pl) 2002-12-23 2006-02-06 Bristol-Myers Squibb Company Sposoby hodowli komórek ssaczych do wytwarzania białka
CA2522779A1 (en) 2003-04-25 2004-11-11 Immunex Corporation Inducers of recombinant protein expression
CN1565631A (zh) * 2003-06-27 2005-01-19 上海中信国健药业有限公司 肿瘤坏死因子受体－免疫球蛋白的融合蛋白用于急性肺损伤药物的用途
ATE464918T1 (de) * 2004-07-07 2010-05-15 Coloplast As Herstellung von hydrophilen überzügen mit einer 1,3-dioxolan-verbindung
TWI384069B (zh) * 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents
US20070102622A1 (en) 2005-07-01 2007-05-10 Olsen Richard I Apparatus for multiple camera devices and method of operating same
DE102005034616B4 (de) * 2005-07-18 2008-07-03 Elringklinger Ag Brennstoffzelleneinheit und Brennstoffzellenstapel
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
PL2041270T3 (pl) * 2006-07-13 2014-04-30 Wyeth Llc Wytwarzanie glikoprotein
CN101679941A (zh) 2007-03-02 2010-03-24 惠氏公司 在细胞培养物中使用铜和谷氨酸盐生产多肽
US20090042253A1 (en) 2007-08-09 2009-02-12 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors

Also Published As

Publication number Publication date
PA8777701A1 (es) 2008-11-19
CN101668845A (zh) 2010-03-10
RU2009138226A (ru) 2011-05-27
ES2646090T3 (es) 2017-12-12
AR066239A1 (es) 2009-08-05
PE20090153A1 (es) 2009-04-23
US20080274507A1 (en) 2008-11-06
JP5881755B2 (ja) 2016-03-09
KR20100017211A (ko) 2010-02-16
US20080269132A1 (en) 2008-10-30
AR066238A1 (es) 2009-08-05
JP2014113161A (ja) 2014-06-26
CO6241166A2 (es) 2011-01-20
CL2008001156A1 (es) 2009-01-16
KR101560421B1 (ko) 2015-10-15
KR101540124B1 (ko) 2015-07-28
CN101668845B (zh) 2015-11-25
HUE034776T2 (en) 2018-02-28
DK2139987T5 (da) 2014-01-27
ES2424217T9 (es) 2014-01-27
RU2009139054A (ru) 2011-05-27
US9988662B2 (en) 2018-06-05
MX2009011363A (es) 2009-11-05
PE20090731A1 (es) 2009-07-15
KR20100016271A (ko) 2010-02-12
AU2008242632A1 (en) 2008-10-30
TW200902709A (en) 2009-01-16
CA2685552C (en) 2016-02-23
EP2139987A1 (en) 2010-01-06
AU2008242632B2 (en) 2013-11-28
AU2008242633A1 (en) 2008-10-30
ES2424217T3 (es) 2013-09-30
PA8778001A1 (es) 2008-11-19
CA2684727C (en) 2018-09-04
DK2139986T3 (en) 2017-10-02
PT2139986T (pt) 2017-11-14
IL201720A0 (en) 2011-08-01
IL201719A (en) 2015-09-24
CN101679943A (zh) 2010-03-24
PL2139986T3 (pl) 2018-01-31
CA2685552A1 (en) 2008-10-30
CA2684727A1 (en) 2008-10-30
SI2139986T1 (sl) 2017-11-30
WO2008131375A1 (en) 2008-10-30
IL201719A0 (en) 2011-08-01
MX2009011362A (es) 2009-11-05
IL201720A (en) 2016-03-31
EP2139986B1 (en) 2017-09-06
HK1142095A1 (zh) 2010-11-26
TW200902708A (en) 2009-01-16
PL2139987T3 (pl) 2013-11-29
JP2010524503A (ja) 2010-07-22
CL2008001159A1 (es) 2008-11-03
JP2010524504A (ja) 2010-07-22
SI2139987T1 (sl) 2013-09-30
EP2139987B1 (en) 2013-07-03
KR20140132016A (ko) 2014-11-14
CN105039473A (zh) 2015-11-11
ZA200907426B (en) 2010-08-25
CO6241165A2 (es) 2011-01-20
PT2139987E (pt) 2013-08-22
HK1216261A1 (zh) 2016-10-28
BRPI0810511A2 (pt) 2014-10-07
WO2008131374A1 (en) 2008-10-30
AU2008242633B2 (en) 2014-09-18
DK2139987T3 (da) 2013-09-02
EP2139987B9 (en) 2013-11-13
JP5557736B2 (ja) 2014-07-23
EP2139986A1 (en) 2010-01-06
RU2478702C2 (ru) 2013-04-10

Similar Documents

Publication Publication Date Title
BRPI0810482A2 (pt) Métodos de produção de proteína usando compostos antissenescência
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
DK2126093T3 (da) Forbedring af proteinfremstilling
DK3118220T3 (da) Protein
ES2752025T8 (es) Métodos de cribado de proteínas
BRPI0814359A2 (pt) Método
BRPI0817226A2 (pt) Método
BRPI0817726A2 (pt) Método
DK2203551T3 (da) Bifidobakterieart
ATE475473T1 (de) Trennverfahren
BRPI0815042A2 (pt) Compostos de pirazol
ATE512201T1 (de) Verbessertes schattierungsverfahren
BRPI0720699A2 (pt) Programas ligados
ATE542825T1 (de) Substituierte piperidino-dihydrothienopyrimidine
BRPI0813500A2 (pt) Compostos antivirais
BRPI0820073A2 (pt) Anticorpos anti-axl
BRPI0812176A2 (pt) Método de cimentar poço
BRPI0814971A2 (pt) Proteína
BRPI0815036A2 (pt) Método de produção de proteína heterogêneas
DK3216802T3 (da) Produktionsfremgangsmåde
BRPI0811264A2 (pt) Compostos
BRPI0814424A2 (pt) Compostos heterociclila
BRPI0911625A2 (pt) Métodos
BRPI0809678A2 (pt) Métodos
BRPI0909633A2 (pt) anticorpos anti-tyrp1

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: WYETH LLC (US)

B25G Requested change of headquarter approved

Owner name: WYETH LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 7.4 NA RPI NO 2544 DE 08/10/2019 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL